Anti-GUCY2C vaccine compositions and methods of using them
AssigneeThomas Jefferson Univerity
InventorsAdam E Snook, Scott A. Waldman, Trevor R Baybutt, John C Flickinger
Life of this patent
Estimating the term…
Abstract
Compositions comprising a modified adenovirus AD5.F35 which includes coding sequence of soluble GUCY2C extracellular domain sequences are disclosed. Compositions comprising a Listeria monocytogenes vector which includes coding sequence of soluble GUCY2C extracellular domain sequences are disclosed. Methods of treating individuals diagnosed with cancer/tumors expressing GUCY2C methods of preventing micro-metastasis are disclosed.
Claims16
A recombinant Ad5.F35 adenovirus comprising:
- a) an adenoviral Ad5.F35 vector which is replication defective and further comprising:
- b) a gene expression cassette comprising:
- i) a heterologous promoter operatively linked to,
- ii) a nucleic acid encoding a soluble human GUCY2C domain as set forth in SEQ ID NO:
- 5 fused in frame to,
- iii) a nucleic acid encoding a universal CD4+ helper epitope PADRE.
A method of treating a human patient diagnosed with cancer, wherein cells of said cancer express GUCY2C, the method comprising the steps of
- a) administering to the patient an effective amount of an injectable pharmaceutical composition comprising
- i) a replication defective recombinant Ad5.F35 adenovirus comprising:
- an adenoviral Ad5.F35 vector further comprising:
- a gene expression cassette comprising:
- a heterologous promoter operatively linked to,
- a nucleic acid encoding a soluble human GUCY2C domain that comprises SEQ ID NO:
- 5 fused in frame to,
- a nucleic acid encoding a universal CD4+ helper epitope;
- and
- b) subsequently administering to the patient an effective amount of an injectable pharmaceutical composition comprising
- i) a recombinant Listeria monocytogenes comprising:
- a gene expression cassette comprising
- a heterologous promoter operatively linked to
- a nucleic acid encoding a soluble human GUCY2C domain.
A method of treating a human patient diagnosed with cancer, wherein cells of said cancer express GUCY2C, the method comprising the steps of
- a) administering to the patient an effective amount of an injectable pharmaceutical composition comprising
- i) a replication defective recombinant Ad5.F35 adenovirus comprising:
- an adenoviral Ad5.F35 vector further comprising:
- a gene expression cassette comprising:
- a heterologous promoter operatively linked to,
- a nucleic acid encoding a soluble human GUCY2C domain fused in frame to,
- a nucleic acid encoding a universal CD4+helper epitope,
- wherein the gene expression cassette of the recombinant Ad5.F35 adenovirus comprises SEQ ID NO:9;
- and
- b) subsequently administering to the patient an effective amount of an injectable pharmaceutical composition comprising
- i) a recombinant Listeria monocytogenes comprising:
- a gene expression cassette comprising
- a heterologous promoter operatively linked to
- a nucleic acid encoding a soluble human GUCY2C domain.
Dependencies are inferred from the claim text.